Karyopharm Therapeutics

Sage Therapeutics, Inc. has a lot to figure out in the coming weeks, now that the US Food and Drug Administration has approved Zurzuvae (zuranolone) for postpartum depression (PPD) but rejected the d

Drug development in hematology-oncology can sometimes happen at such a fast, paradigm-busting pace that the selection of treatments even 20 years ago can look like prehistory compared to what is avail

Chinese pharma companies are now taking some of their principal products to the smaller global markets of Southeast Asia, which a number are targeting in an expansion push. Hong Kong- and Shanghai-lis

Johnson & Johnson stands to hit another milestone in multiple myeloma with the likely approval of its bispecific antibody talquetamab as the first drug on the market targeting GPRC5D as well as CD3.